Program Updates and Recent ProgressLX2006 in Friedreich Ataxia (FA)In June 2026, Lexeo finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) for LX2006 under the accelerated approval pathway. Research & Development Expenses: Research and Development expenses were $19.0 million for the three months ended June 30, 2026, compared to $14.7 million for the three months ended June 30, 2025. Research and Development expenses were $19.0 million for the three months ended June 30, 2026, compared to $14.7 million for the three months ended June 30, 2025. General & Administrative Expenses: General and Administrative expenses were $9.0 million for the three months ended June 30, 2026, compared to $16.0 million for the three months ended June 30, 2025. General and Administrative expenses were $9.0 million for the three months ended June 30, 2026, compared to $16.0 million for the three months ended June 30, 2025.